Business Wire

KIRIN Develops Technology to Enhance Heat and Drought Tolerance in Hop Seedlings Contributing to a Sustainable Supply of Beer Ingredients Amid Climate Change

26.9.2025 04:44:00 EEST | Business Wire | Press release

Share

Kirin Holdings Company, Limited (Kirin) (TOKYO: 2503) has developed a seedling cultivation technology that enhances heat and drought tolerance in hops through acquired tolerance, helping to address the growing challenges of reduced yield and quality caused by extreme heat and drought. This method enables hops to gain resilience without compromising flavor quality, and is expected to contribute to a more sustainable and stable supply of beer ingredients. This technology was presented at the Scientific-Technical Commission of the International Hop Growers' Convention in June 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924957521/en/

Field trial in Iwate Prefecture. Variety: Saaz. Left: untreated control plants; Right: heat-treated plants.

Background of the Research

  • Global warming is known to act as heat stress on plants, inhibiting their growth*1. Hops, which prefer cool climates, suffer from poor growth under high temperatures and dry conditions, leading to declining yields and quality worldwide. This raises concerns about rising raw material costs and impacts on product quality, necessitating the development of technologies enabling stable cultivation and procurement even under climate change.

*1 In plants, temperatures higher than their optimal growth range cause heat stress. This can lead to delayed growth and symptoms such as leaf whitening.

Research Overview

  • Leveraging Kirin’s long-standing expertise in plant cultivation technologies*2 , we have developed a seedling production technique to induce heat tolerance and drought tolerance in hop seedlings. This is achieved by growing the seedlings in a liquid medium and applying a six-week heat treatment at 25°C during the mass propagation process. Unlike traditional breeding or genetic modification, this technique allows hops to acquire resilience without altering their original aroma or flavor profile. This research was evaluated using the Czech variety “Saaz” and the German variety “Hersbrucker.”

*2 Kirin Succeeds in Developing the World’s First Technology to Promote Axillary Bud Formation in Hops—A Breakthrough in Mass Propagation of Hop Plants (Website in Japanese)

Research Findings

Laboratory evaluation of high-temperature and dry environments

  • In laboratory tests simulating high-temperature and drought-conditions*3, heat-treated hop plants exhibited significantly higher plant height and chlorophyll*4 content compared to untreated control plants, demonstrating improved growth and enhanced tolerance.

*3 Drought condition testing was conducted using the “Saaz” variety only.
*4 Chlorophyll is a natural green pigment essential for photosynthesis. As leaves wither, they turn white or yellow due to reduced chlorophyll levels.

Cultivation evaluation at the test field

  • In cultivation evaluations conducted in Esashi City, Iwate Prefecture, heat-treated hop plants showed significantly higher plant height and above-ground weight compared to untreated control plants, and tended to produce higher cone yields.

Future Outlook

  • Moving forward, we will advance the refinement of mass seedling production technology, elucidate physiological changes induced by heat treatment, and verify applicability across multiple fields and varieties, while exploring implementation overseas. Our company aims to contribute to the realization of a sustainable beer ingredient supply.

The Kirin Group will continue to tackle complex and interrelated environmental issues (biological resources, water resources, containers and packaging, and climate change) in an integrated manner, and to work together with all those involved in the value chain to link our desire to enjoy and pass on the bounty of the Earth’s abundance to future generations. We will actively promote various initiatives that have a ‘positive impact’ on nature and people.

Reference: Kirin’s Environmental Initiatives

Kirin Group's Environmental Vision 2050 | The Environment | KIRIN - Kirin Holdings Company, Limited
Kirin Group Environmental Report | Sustainability Information | KIRIN - Kirin Holdings Company, Limited

Attachment: "Research Findings"

Background and Objective

  • Hops are a dioecious vine plant belonging to the Cannabaceae family. The female flowers, known as strobili, contain diverse secondary metabolites that impart bitterness, aroma, and antimicrobial properties to beer, making them an essential ingredient in brewing. Hops are plants that prefer cool climates and are primarily cultivated in regions between 35° and 55° north and south latitude, such as Europe, North America, and Australia. In response to recent declines in hop yield and quality due to rising temperatures and drought, accelerating Research and Development on climate change adaptation—including breeding improvements and cultivation techniques—to achieve sustainable raw material procurement has become an urgent priority.

Research Methodology

  • Methods for conferring stress tolerance to plants include breeding, genetic modification, the use of biostimulants, and environmental condition control. This study selected environmental condition control, as it is expected to have minimal impact on flavor. Specifically, we developed a technique to confer acquired heat and drought tolerance by growing hop seedlings in liquid medium and applying a six-week heat treatment at 25°C during the propagation process. This study evaluated the Czech variety “Saaz” and the German variety “Hersbrucker”.

Research Findings

1. Stress Tolerance Evaluation in Laboratory Conditions

  • In tests conducted under both high-temperature and drought-conditions *5, heat-treated hop plants showed significantly higher plant height and chlorophyll content compared to untreated control plants, confirming improved growth and enhanced tolerance.

*5 Drought condition testing was conducted using the “Saaz” variety only.

2. Field Evaluation in Japan

  • In April 2023, heat-treated plants and untreated control plants were planted in Esashi City and Tono City, both located in Iwate Prefecture, and evaluated over a two-year period.
  • In Esashi City, where the average temperature from May to September is approximately 2°C higher than in Tono City, heat-treated plants showed a significant tendency toward larger aboveground weight and higher boll yield compared to untreated control plants. No significant difference was observed in Tono City, where temperatures are lower than in Esashi City.

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.

Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.

Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.

*: Creating Shared Value. Combined added value for consumers as well as for society at large.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250924957521/en/

Contacts

Press Contact
Corporate Communication Department
Kirin Holdings Company, Limited
Nakano Central Park South, 4-10-2 Nakano, Nakano-ku, Tokyo
+81-3-6837-7028
Media Inquiries | KIRIN - Kirin Holdings Company, Limited -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffaq.kirin.co.j
p%2Fform%2Fkh_10_en.html&esheet=54329484&newsitemid=20250924957521&lan=en-US&anc
hor=Media+Inquiries+%7C+KIRIN+-+Kirin+Holdings+Company%2C+Limited&index=4&md5=e7
0dc75e6cff94d774c8ebf778c2ed72
https://www.kirinholdings.com/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kirinholdi
ngs.com%2Fen%2F&esheet=54329484&newsitemid=20250924957521&lan=en-US&anchor=https
%3A%2F%2Fwww.kirinholdings.com%2Fen%2F&index=5&md5=6d6b12e38f8b7be88f6cd17d2c9a9
57e
kirin-cc@kirin.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye